头孢噻肟在革兰氏阳性菌肺炎治疗中的应用。

The use of cefotaxime in the treatment of gram-positive pneumonias.

作者信息

Jenkinson S G

出版信息

Infection. 1985;13 Suppl 1:S14-7. doi: 10.1007/BF01644211.

Abstract

A single-blind, prospective, randomized comparison of cefotaxime and cefazolin was conducted in 356 patients with gram-positive pneumonias. Clinical cure was achieved in 95.9% of patients receiving cefotaxime and 94% of patients receiving cefazolin. In a sub-group of patients with Staphylococcus aureus pneumonia, clinical cure was obtained in 31 of 37 patients treated with cefotaxime and all of six patients treated with cefazolin. Cefotaxime was well tolerated, safe, and efficacious. These data support the use of cefotaxime as an initial single antibiotic in treating patients with gram-positive pneumonias due to susceptible organisms.

摘要

对356例革兰氏阳性肺炎患者进行了头孢噻肟和头孢唑林的单盲、前瞻性、随机对照试验。接受头孢噻肟治疗的患者中95.9%实现了临床治愈，接受头孢唑林治疗的患者中这一比例为94%。在金黄色葡萄球菌肺炎患者亚组中，接受头孢噻肟治疗的37例患者中有31例实现了临床治愈，接受头孢唑林治疗的6例患者全部实现临床治愈。头孢噻肟耐受性良好、安全且有效。这些数据支持将头孢噻肟作为治疗由敏感菌引起的革兰氏阳性肺炎患者的初始单一抗生素。